S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
OTCMKTS:PHGUF

Pharming Group Stock Forecast, Price & News

$0.92
-0.03 (-3.16 %)
(As of 09/24/2021 02:13 PM ET)
Add
Compare
Today's Range
$0.92
$0.92
50-Day Range
$0.92
$1.16
52-Week Range
$0.92
$1.85
Volume52,630 shs
Average Volume6,523 shs
Market Capitalization$575.81 million
P/E Ratio23.01
Dividend YieldN/A
Beta1.65
30 days | 90 days | 365 days | Advanced Chart
Receive PHGUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.


Pharming Group logo

About Pharming Group

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.00 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pharming Group (OTCMKTS:PHGUF) Frequently Asked Questions

Is Pharming Group a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Pharming Group stock.
View analyst ratings for Pharming Group
or view top-rated stocks.

What stocks does MarketBeat like better than Pharming Group?

Wall Street analysts have given Pharming Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pharming Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pharming Group?

Pharming Group saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 6,276,900 shares, a decline of 48.2% from the July 29th total of 12,110,700 shares. Based on an average daily volume of 21,300 shares, the days-to-cover ratio is presently 294.7 days.
View Pharming Group's Short Interest
.

When is Pharming Group's next earnings date?

Pharming Group is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Pharming Group
.

How were Pharming Group's earnings last quarter?

Pharming Group (OTCMKTS:PHGUF) posted its earnings results on Thursday, August, 5th. The biotechnology company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The biotechnology company had revenue of $49.67 million for the quarter, compared to the consensus estimate of $67.16 million. Pharming Group had a trailing twelve-month return on equity of 17.91% and a net margin of 15.39%.
View Pharming Group's earnings history
.

How has Pharming Group's stock price been impacted by COVID-19 (Coronavirus)?

Pharming Group's stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHGUF stock has decreased by 31.9% and is now trading at $0.92.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PHGUF?

1 brokers have issued twelve-month price targets for Pharming Group's stock. Their forecasts range from $3.10 to $3.10. On average, they expect Pharming Group's stock price to reach $3.10 in the next twelve months. This suggests a possible upside of 237.0% from the stock's current price.
View analysts' price targets for Pharming Group
or view top-rated stocks among Wall Street analysts.

Who are Pharming Group's key executives?

Pharming Group's management team includes the following people:
  • Sijmen de Vries, Chief Executive Officer & Executive Director
  • Mireille Sanders, Senior Vice President-Operations
  • Jeroen Henk Wakkerman, Chief Financial Officer
  • Robert Friesen, Chief Scientific Officer
  • Anurag Relan, Chief Medical Officer

Who are some of Pharming Group's key competitors?

What is Pharming Group's stock symbol?

Pharming Group trades on the OTCMKTS under the ticker symbol "PHGUF."

How do I buy shares of Pharming Group?

Shares of PHGUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHGUF stock can currently be purchased for approximately $0.92.

How much money does Pharming Group make?

Pharming Group has a market capitalization of $575.81 million and generates $212.10 million in revenue each year. The biotechnology company earns $37.74 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Pharming Group have?

Pharming Group employs 262 workers across the globe.

What is Pharming Group's official website?

The official website for Pharming Group is www.pharming.com.

Where are Pharming Group's headquarters?

Pharming Group is headquartered at Darwinweg 24, Leiden P7, 2333 CR.

How can I contact Pharming Group?

Pharming Group's mailing address is Darwinweg 24, Leiden P7, 2333 CR. The biotechnology company can be reached via phone at (171) 524-7400 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.